The group claims to have no conflicts of interest, no vested financial interest in the issue of drug shortages and no outside funding. But the financial ties to drug and medical device companies of Stanford Professor Emeritus Dr. Brock-Utne and other co-chairs call these claims into question.
A Senate Investigative Subcommittee and 60 Minutes report that Kaleo’s Evzio drug skyrocketed 600%, costing taxpayers millions. Yet that didn’t stop leaders of Physicians Against Drug Shortages (PADS) from promoting another of the pharmaceutical company’s drugs.
Recent Comments